6,778 Shares in Boston Scientific Corporation $BSX Purchased by Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,778 shares of the medical equipment provider’s stock, valued at approximately $728,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BSX. Sound Income Strategies LLC boosted its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the first quarter worth $26,000. Kilter Group LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $30,000. Princeton Global Asset Management LLC acquired a new position in Boston Scientific in the second quarter valued at $32,000. Finally, Howard Hughes Medical Institute purchased a new position in Boston Scientific during the second quarter worth about $34,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 143,095 shares of company stock worth $14,228,950 in the last 90 days. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have commented on BSX. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, Robert W. Baird increased their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Stock Performance

NYSE:BSX opened at $93.66 on Tuesday. The firm’s fifty day simple moving average is $99.20 and its 200 day simple moving average is $101.95. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The firm has a market capitalization of $138.84 billion, a price-to-earnings ratio of 50.08, a PEG ratio of 1.96 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the company posted $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.